The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial
Abstract
NOTCH1 and SF3B1 mutations have been previously reported to have prognostic significance in chronic lymphocytic leukemia but to date they have not been validated in a prospective, controlled clinical trial. We have assessed the impact of these mutations in a cohort of 494 patients treated within the randomized phase 3 United Kingdom Leukaemia Research Fund Chronic Lymphocytic Leukemia 4 (UK LRF CCL4) trial that compared chlorambucil and fludarabine with and without cyclophosphamide in previously untreated patients. We investigated the relationship of mutations in NOTCH1 (exon 34) and SF3B1 (exon 14-16) to treatment response, survival and a panel of established biologic variables. NOTCH1 and SF3B1 mutations were found in 10% and17% of patients, respectively. NOTCH1 mutations correlated with unmutated IGHV genes, trisomy 12, high CD38/ ZAP-70 expression and were associated with reduced overall (median 54.8 vs 74.6 months, P = .02) and progression-free (median 22.0 vs 26.4 months, P = .02) survival. SF3B1 mutations were significantly associated with high CD38 expression and with shorter overall survival (median 54.3 vs 79.0 months, P < .001). Furthermore, multivariate analysis, including baseline clinical variables, treatment, and adverse prognostic factors demonstrated that although TP53 alterations remained the most informative marker of dismal survival in this cohort, NOTCH1 (HR 1.58, P = .03) and SF3B1 (HR 1.52, P = .01) mutations have added independent prognostic value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Self-citation
Cited by
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stilgenbauer, S., Schnaiter, A., Paschka, P., Zenz, T., Rossi, M., Döhner, K., Bühler, A., Böttcher, S., Ritgen, M., Kneba, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-546150 · Cited by 516
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.018 · Cited by 374
Nadeu, F., Delgado, J., Royo, C., Baumann, T., Stankovic, T., Pinyol, M., Jares, P., Navarro, A., Martín-García, D., Beà, S., et al. (2016) · Blood · doi:10.1182/blood-2015-07-659144 · Cited by 336
Recurrent mutations refine prognosis in chronic lymphocytic leukemia
Baliakas, P., Hadzidimitriou, A., Sutton, L.-A., Rossi, D., Minga, E., Villamor, N., Larrayoz, M., Kminkova, J., Agathangelidis, A., Davis, Z., et al. (2015) · Leukemia · doi:10.1038/leu.2014.196 · Cited by 287
Self-citation
Metadata
- Authors
- Oscier, D. G., Rose-Zerilli, M. J. J., Winkelmann, N., Gonzalez de Castro, D., Gomez, B., Forster, J., Parker, H., Parker, A., Gardiner, A., Collins, A., Else, M., Cross, N. C. P., Catovsky, D., & Strefford, J. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-01-17
- Volume
- 121
- Issue
- 3
- Pages
- 468-475
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2010779916
- Cited by
- 214
- References
- 2
- FWCI
- 11.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. https://app.cochat.ai/papers/10.1182/blood-2012-05-429282
- The paper
- Oscier, D. G., Rose-Zerilli, M. J. J., Winkelmann, N., Gonzalez de Castro, D., Gomez, B., Forster, J., Parker, H., Parker, A., Gardiner, A., Collins, A., Else, M., Cross, N. C. P., Catovsky, D., & Strefford, J. C. (2013). The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. https://doi.org/10.1182/blood-2012-05-429282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.